Moderna MRNA has been at the center of a series of developments, particularly involving its
bird flu vaccine funding from the Trump administration. Questions have been raised regarding the continuation of this funding. The Health department is reportedly considering pulling the funding despite outbreaks, as it revamps the government's approach to dealing with public health issues. Parallel to this,
Moderna is dealing with potential problems on the performance of its bird flu vaccine and a halt to its norovirus vaccine trial over neurological side effects. Despite these challenges, there are achievements in
Moderna's mRNA field. The company has received MHRA marketing authorization for its RSV vaccine and reported positive Phase III data for its COVID-19/Influenza vaccine. It also announced a free course on mRNA medicines, and the House rejected a bill to ban mRNA vaccines in Montana. While its earnings top revenue estimates, the company has been faced with patent infringement by GSK. There has been significant unusual options activity and some fluctuations in the stock's performance.
Moderna MRNA News Analytics from Fri, 31 May 2024 07:00:00 GMT to Sat, 01 Mar 2025 15:43:39 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 1
